Novogenia AG
Novogenia AG is the stock-listed parent company of Novogenia GmbH.
PERSONALIZED products, services and therapies based on YOUR unique BIOLOGICAL DATA
Novogenia AG harnesses advances in biotechnology and artificial intelligence to create highly personalized solutions from scientific lab-analysis data — spanning genetic testing, personalized supplements and cosmetics, and advanced therapies (personalized infusion therapies and IVF / reproductive genetics). The Group is the listed holding company (ISIN DE000A3C35W0), traded on XETRA and the Munich Stock Exchange.
New headquarters & laboratory
Our mission
Analyse. Learn. Solve. Explore. — the principle behind every Novogenia product.
Analyse
Using advanced technologies in our laboratories to decypher the human genome and metabolome.
- Genetic analysis for optimized nutrition
- Disease prevention & therapy optimization
- Virological & diagnostic analyses
- Genetic analysis for IVF improvement
Learn
Using artificial intelligence to interpret genetic data for unparalleled insights into the body.
- AI-powered identification of genetic traits
- Detect inefficiencies in therapies via lab analytics
- “Analyse → product → re-analyse” feedback loop
- Decypher millions of scientific publications
Solve
Based on unique personal data, personalized solutions are produced for each individual.
- Genetic reports with personalized action plans
- Personalized supplements & cosmetics
- Optimized therapies and IVF cycles
- Personalized drug development as infusions
Explore
Applying the principle of Analyse · Learn · Solve across healthcare and biotechnology.
- Acquisitions in the healthcare and biotech sector
- In-house startups to expand the portfolio
- Clinical studies to assess product performance
Our companies
The operating companies and strategic investments organised under Novogenia AG.
Novogenia GmbH100%
NovoMedic GmbH70%
Mendelio Srl70%
Medicopharm AG100%
INOPHA GmbH51%
ChiruTec GmbH51%
Nephrogen Inc.Business segments & companies
All brands & companies →Three operating divisions — Diagnostics & Personalized Products (€52M cash reserves), Drug Import & Medical Devices, and Minority Investments (€10.6M invested) — plus the Group’s full company org chart and revenue-by-segment charts.
Explore the full Group structure & segments →
Company achievements
A fully integrated value chain — everything from laboratory to finished product, in house.
Our global market
A globally active group — with resellers and customers across the world.

New building & expansion
A €35 million investment in the next decade of capacity.

New building & capacity expansion
Novogenia is investing €35 million in a new, state-of-the-art headquarters and laboratory complex — massively expanding diagnostic, supplement and cosmetics production capacity to meet accelerating global demand. The Group expects to move into the new building at the end of 2027.
- Expanded high-throughput genetic laboratory
- Scaled in-house supplement & cosmetics manufacturing
- Automation and additional clean-room capacity
- Room for the next decade of growth
Inside Novogenia
Tour through the Novogenia Facility
Step inside our Salzburg headquarters — the accredited high-throughput genetic and blood laboratory, the in-house supplement and cosmetics manufacturing, and the teams that run the full value chain from sample to finished product.
Media
Films from the Novogenia Academy — the science behind our analyses and products.
Get Certified
NOVO Academy is the group’s online education platform — structured courses, expert talks and certifications on human genetics, personalized nutrition and cosmetics, and how to put DNA-based analysis to work in everyday practice. Built for partners, health professionals and curious customers alike.
- Genetics & personalized-health fundamentals
- Certified courses for partners & professionals
- Expert talks and continuously updated science
Investor & press contact
Questions from shareholders, analysts or media? Our Investor Relations team is happy to help.
